Condition: Enteric Hyperoxaluria · Primary Hyperoxaluria · Hyperoxalemia · Sponsor: Allena Pharmaceuticals
Evaluate the efficacy and safety of ALLN-177 in reducing plasma and urinary oxalate levels in adult and pediatric patients with enteric hyperoxaluria and hyperoxalemia or primary hyperoxaluria
This description comes directly from the study's public registry record.
Contact details are listed per location below or on the registry record.
Always discuss trial participation with your own doctor first.
| Mayo Clinic | Scottsdale, Arizona, United States | — |
| Applied Research Center of Arkansas | Little Rock, Arkansas, United States | — |
| Yale University School of Medicine | New Haven, Connecticut, United States | — |
| Mayo Clinic | Rochester, Minnesota, United States | — |
| Charite Campus Berlin-Mitte, Medizinische Klinik mit Schwepunkt Nephrologie und Internistische Intensivmedizin | Berlin, Germany | — |
| Wellcome Trust Clinical Research Facility | Southampton, Hampshire, United Kingdom | — |
| Royal Preston Hospital | Preston, Lancashire, United Kingdom | — |
| Leeds General Infirmary | Leeds, United Kingdom | — |
| Freeman Hospital | Newcastle, United Kingdom | — |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT03391804